NCT01240148

Determine the Effect of AZD3161,Injected Intradermally, on Quantitative Sensory Testing Variables in Normal and Ultraviolet-C (UVC) Exposed Skin in Healthy Volunteers

A Randomised, Double-Blind, Placebo-Controlled, Single-Centre Study to Determine the Effect of Intradermal AZD3161 on Quantitative Sensory Testing Variables in Normal and UVC Exposed Skin in Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 26 (actual)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to investigate the effect of AZD3161 on mechanical pain sensitivity and axon reflex flare in normal and ultraviolet C irradiated skin.

Conditions

• Peripheral Neuropathic Pain
• Nociceptive Pain

Interventions

Type	Name	Description
DRUG	AZD3161	Single dose, intradermal injection
DRUG	Lidocaine	Single dose, intradermal injection
DRUG	AZD3161 Placebo

Timeline

• Start date: 2010-12-01
• Primary completion: 2011-03-01
• Completion: 2011-03-01
• First posted: 2010-11-15
• Last updated: 2011-04-12

Locations

1 site across 1 country: United Kingdom